Glenmede Trust’s PDL BioPharma, Inc. PDLI Stock Holding History

Glenmede Trust’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-206	Closed	–	–	2838
2020 Q1	$0	Hold	206	–	–	﹤0.01%	3118
2019 Q4	$0	Hold	206	–	–	﹤0.01%	3248
2019 Q3	$0	Hold	206	–	–	﹤0.01%	3243
2019 Q2	$0	Hold	206	–	–	﹤0.01%	3299
2019 Q1	$0	Hold	206	–	–	﹤0.01%	3311
2018 Q4	$0	Buy	+206	New	+$566	﹤0.01%	3175
2017 Q4	–	Sell	-393	Closed	-$1K	–	2934
2017 Q3	$1K	Hold	393	–	–	﹤0.01%	2693
2017 Q2	$0	Hold	393	–	–	﹤0.01%	2759
2017 Q1	$0	Hold	393	–	–	﹤0.01%	2869
2016 Q4	$0	Hold	393	–	–	﹤0.01%	2771
2016 Q3	$1K	Hold	393	–	–	﹤0.01%	2547
2016 Q2	$1K	Sell	393 -1,294	-77%	-$4.32K	﹤0.01%	2520
2016 Q1	$5K	Buy	1,687 +1,319	+358%	+$4.11K	﹤0.01%	2240
2015 Q4	$1K	Sell	368 -100	-21%	-$419	﹤0.01%	2621
2015 Q3	$2K	Buy	+468	New	+$2.68K	﹤0.01%	2560

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Glenmede Trust's PDLI Position: Q2 2020 in Review

Glenmede Trust sold out of PDL BioPharma, Inc. (PDLI) in Q2 2020, closing a stake of 206 shares.

Glenmede Trust first reported a position in PDLI in Q3 2015 and held it in 15 quarters. The position peaked at $5K in Q1 2016. 136 funds tracked by Wall St. Rank hold PDLI as of Q2 2020.

Glenmede Trust reported no remaining PDL BioPharma, Inc. position as of Q2 2020 after selling out during the quarter.
Glenmede Trust sold 206 PDL BioPharma, Inc. shares in Q2 2020.
Glenmede Trust first reported a position in PDL BioPharma, Inc. in Q3 2015 and held it in 15 quarters.
Glenmede Trust's PDL BioPharma, Inc. position peaked at $5K in Q1 2016.
136 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2020.

Based on Glenmede Trust's 13F filing for Q2 2020, filed 14 Aug 2020.